Ezra, the healthcare AI startup transforming early cancer detection through full body MRI screening, announced a partnership with RAYUS Radiology, a leading provider of imaging services. The partnership will enable Ezra to expand nationally in 150 RAYUS locations across the U.S.
Ezra utilizes medical imaging and Artificial Intelligence to monitor for possible cancer and 500+ conditions in up to 13 organs, giving individuals the ability to detect diseases at an earlier stage. Partnering with RAYUS is part of Ezra’s vision to bring the most advanced early cancer detection technology to everyone.
“Until recently, medical imaging was principally used for the diagnosis and characterization of disease once a patient is symptomatic,” said Daniel K. Sodickson, MD, PhD, Chief of Innovation in the Department of Radiology at NYU Stern, and a scientific advisor to Ezra. “Ezra is using MRI as a tool for early detection of cancer prior to the development of symptoms, and leverages AI technology to minimize overdiagnosis and false positives. I’m excited to see Ezra bringing their technology to more facilities in the U.S.”
“More than 1.9 million people will be diagnosed with cancer in the U.S. in 2024, according to the American Cancer Society, and half of them will be diagnosed late. Cancer is most curable when detected early, and our mission at Ezra is to detect cancer early for everyone in the world. I’m incredibly excited to be working with RAYUS on making Ezra available to more people in the U.S., and look forward to saving lives together,” said Emi Gal, founder and CEO of Ezra.
Ezra is the first company globally to leverage AI across all three key components of the cancer screening process: imaging, analysis and reporting, and a direct-to-consumer offering. The Ezra Flash AI enables Ezra to acquire MRI scans faster and enhance their quality; Ezra Prostate AI assists radiologists in the analysis of MR images of the prostate; and Ezra Reporter AI creates an easily digestible translation of radiology reports that assist medical professionals in communicating screening results to people.
“After careful due diligence, we are excited to make Full Body MRI screening available through our nationwide network of imaging facilities via our technology partnership with Ezra, the AI leaders in this space,” said Kim Tzoumakas, RAYUS Radiology CEO.
Ezra’s newest proprietary Artificial Intelligence, Ezra Flash, received 510(k) clearance by the U.S. Food and Drug Administration (FDA) in May 2023. The AI enhances the quality of MR images, making it possible for Ezra to decrease the time needed to complete a high quality scan, thereby reducing MRI cost.
SOURCE: GlobeNewsWire
